Search results
Showing 181 to 195 of 379 results for lung cancer
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]
Discontinued Reference number: GID-TA10633
Vandetanib for the second line treatment of non-small cell lung cancer [ID46]
Discontinued Reference number: GID-TAG405
Awaiting development Reference number: GID-TA11626 Expected publication date: TBC
Awaiting development Reference number: GID-TA12003 Expected publication date: TBC
Awaiting development Reference number: GID-TA11828 Expected publication date: TBC
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer [ID1228]
Discontinued Reference number: GID-TA10203
Discontinued Reference number: GID-TA10233
IMI and H2020 Grant funded projects with NICE
Discontinued Reference number: GID-TA10271
Discontinued Reference number: GID-TA10697
Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]
Discontinued Reference number: GID-TA10341
clinician review in detecting nodules or other abnormal lung features that suggest lung cancer the diagnostic accuracy of...
Discontinued Reference number: GID-TA10365
Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]
Discontinued Reference number: GID-TA10585
Discontinued Reference number: GID-TA10413